Comparative Pharmacology
Head-to-head clinical analysis: ACYCLOVIR versus BKEMV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACYCLOVIR versus BKEMV.
ACYCLOVIR vs BKEMV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclovir is a synthetic nucleoside analog that inhibits viral DNA replication. It is phosphorylated to acyclovir monophosphate by viral thymidine kinase, then converted to acyclovir triphosphate by cellular kinases. Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase, incorporating into viral DNA and causing chain termination.
BKEMV is a monoclonal antibody that binds to the extracellular domain of the HER2/neu receptor, inhibiting downstream signaling pathways including PI3K/Akt and MAPK, thereby reducing cell proliferation and promoting antibody-dependent cell-mediated cytotoxicity (ADCC).
400 mg orally twice daily for herpes zoster; 200 mg orally 5 times daily for genital herpes; 5-10 mg/kg intravenously every 8 hours for severe infections.
Intravenous: 100 mg every 12 hours; oral: 50 mg twice daily.
None Documented
None Documented
Clinical Note
moderateAcyclovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Acyclovir."
Clinical Note
moderateTizanidine + Acyclovir
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Terminal elimination half-life is 2.5–3.3 hours in adults with normal renal function; increases to 19.5 hours in anuria.
Terminal elimination half-life: 12-18 hours in healthy adults; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 62-90% of elimination. Fecal elimination is <2%.
Renal excretion: 40-50% unchanged; biliary/fecal: 20-30% as metabolites; total clearance approximates renal clearance.
Category A/B
Category C
Antiviral
Antiviral, HIV